In accordance with the Announcement of the National Medical Products Administration (NMPA) on Further Improving Matters Related to the Associated Review, Approval and Regulation of Drugs (Announcement No. 56 of 2019), KornnacCaps empty capsule products have officially completed the filing and registration as a pharmaceutical excipient with the Center for Drug Evaluation (CDE) of the NMPA. The relevant registration information is now publicly available on the official CDE website. This milestone marks significant progress in KornnacCaps's product quality management and regulatory compliance system, laying a solid foundation for the company's deep participation in the drug-associated review and approval process.

Announcement No. 56 (2019) represents a key measure by the state to deepen the reform of drug review and approval systems and encourage pharmaceutical innovation. The Announcement clarifies the management requirements for the associated review and approval of raw materials, excipients, and packaging materials (together with drug formulations), stipulating that excipient registrants must submit registration dossiers through the CDE platform, which drug formulation applicants may reference and associate with during their application submissions. Completing this registration means that the registrant's quality management system, manufacturing processes, and product quality standards have been incorporated into the national drug regulatory framework and are subject to full regulatory oversight.
As a professional manufacturer of pharmaceutical empty capsules, KornnacCaps has always adhered to the philosophy of "quality by design and compliance throughout the entire process". The company has established and operates a quality management system strictly in line with pharmaceutical excipient requirements. From raw material procurement and production process control to finished product release, rigorous testing and traceability procedures are implemented to ensure product safety, stability, and controllability, fully meeting downstream formulation customers' requirements for functionality and safety.
The completion of this CDE registration carries multiple significances: Firstly, KornnacCaps's product information has officially entered the national pharmaceutical excipient registration platform, enabling downstream drug formulation companies to directly reference and associate with the product, effectively shortening the review cycle for formulation applications. Secondly, it further validates the conformity of the company's quality system with national regulatory requirements, enhancing the product's credibility and competitiveness in the market. Thirdly, it provides strong support for the company's subsequent product upgrades and international market expansion.
The company stated that, it will continue to increase investment in quality and technological innovation, continuously improve the quality and service level of its hollow capsule products, provide formulation customers with compliant, high-quality, and reliable product assurance, and actively contribute to the high-quality development of China's pharmaceutical industry.
